Glucagon-like peptide-1 receptor agonists and new-onset atrial fibrillation in adults with diabetes or obesity: a multinational cohort study
Main finding · New-onset AFResult — go to the resultHazard ratio 0.924 95% CI 0.881–0.969Authors' conclusion
GLP-1RA therapy was associated with reduced incidence of new-onset AF, particularly among adults with diabetes.
Study context
- Population
- Adults aged ≥ 20 years with diabetes or obesity, 2017–2021, TriNetX network (>220 healthcare organizations, 30 countries); follow-up up to three yearsmatched cohort
- Participants
- 137,200 vs 137,200
- Exposure
- GLP-1 RA initiators vs non-GLP-1 RA active comparators
- GLP-1RAn = 137,200
- Non-GLP-1RAn = 137,200reference
- Outcome
- New-onset atrial fibrillation (AF) identified by ICD-10 codes after a 90-day exclusion window
- Follow-up
- Up to three years
Methodological detailsmultinational, 1:1 propensity score matching, active comparator
- Multinational
- 1:1 propensity score matching
- Active comparator
Main finding
New-onset AF
Hazard ratio
0.924
95% CI 0.881–0.969
GLP-1RAvs Non-GLP-1RA active comparators
HR 0.924 (95% CI 0.881–0.969)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| New-onset AF, diabetes cohort,vs DPP-4i | 0.723 (0.675–0.774) | |
| New-onset AF, obesity cohort,vs non-sympathomimetic agents17,737 per group | 0.765 (0.628–0.933) | |
| 0.512Hazard ratio (log scale) |
Original publication
Glucagon-like peptide-1 receptor agonists and new-onset atrial fibrillation in adults with diabetes or obesity: a multinational cohort study. Diabetes Res Clin Pract. Published 21 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →